Suchergebnisse - "Camidge, D Ross"

PubPharm (81)

1

Mobocertinib : Mechanism of action, clinical, and translational science

enthalten in: Clinical and translational science | 2024

von Hanley, M. | Camidge, D. | Fram, R. | +1

2

CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression

enthalten in: Clinical lung cancer | 2024

von Jurica, J. | Carsten, B. | Balakhani, S. | +3

3

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC : A Brief Report

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Kim, D. | Kim, S. | Camidge, D. | +13

CommentIn: J Thorac Oncol. 2023 May;18(5):552-555. - PMID 37087115

4

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

enthalten in: Cancer discovery | 2023

von Drilon, A. | Horan, J. | Tangpeerachaikul, A. | +21

5

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Camidge, D. | Barlesi, F. | Goldman, J. | +15

CommentIn: Transl Lung Cancer Res. 2023 Aug 30;12(8):1826-1829. - PMID 37691875

6

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer : Final Results From the Phase III ALTA-1L Study

enthalten in: Clinical lung cancer | 2022

von Ahn, M. | Kim, H. | Yang, J. | +18

7

The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer : A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX)

enthalten in: Clinical lung cancer | 2022

von Bang, T. | Hu, J. | Patil, T. | +7

8

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L

enthalten in: Current medical research and opinion | 2022

von Reckamp, K. | Lin, H. | Cranmer, H. | +7

9

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States

enthalten in: The oncologist | 2022

von Jahanzeb, M. | Lin, H. | Wu, Y. | +7

10

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

enthalten in: Cancer discovery | 2022

von Wang, M. | Yang, J. | Mitchell, P. | +22

1
2
3
4
5
6
7
8
9
Nächster »
[9]